Prostate Cancer

Walter M. Stadler, MD, Fred C. Buffett Professor of Medicine and Surgery, dean for clinical research, director of the Genitourinary Oncology Program, and deputy director of the Comprehensive Cancer Center, at the University of Chicago Medicine, discusses the use of active surveillance in prostate cancer.

Winston Tan, MD, hematologist/oncologist, Mayo Clinic, discusses the FDA approval of darolutamide (Nubeqa) in nonmetastatic castration-resistant prostate cancer (M0CRPC).

The FDA has approved darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Leonard G. Gomella, MD, discusses the role of prostate-specific antigen screening in the early detection of prostate cancer.

Deborah A. Bradley, MD, medical oncologist, Levine Cancer Institute, Atrium Health, discusses the adverse events (AEs) that are associated with enzalutamide (Xtandi) and apalutamide (Erleada) in prostate cancer.

Daniel Vaena, MD, hematologist/medical oncologist and hematologist, West Cancer Center, discusses progress made in the treatment of patients with metastatic prostate cancer.

Evan Y. Yu, MD, professor, Department of Medical Oncology, University of Washington School of Medicine, member, Clinical Research Division, Fred Hutchinson Cancer Research Center, and clinical trials core director, Genitourinary Medical Oncology, Seattle Cancer Care Alliance, discusses future directions in prostate cancer.

Celestia S. Higano, MD, FACP, shares insight on key trials in prostate cancer.